SPECIAL NOTICE
A -- Cellular Therapy for the Treatment of Hemorrhagic Shock (CTTHS) - MTEC-17-03-Cellular Therapy for the Treatment of Hemorrhagic Shock (CTTHS)
- Notice Date
- 7/14/2017
- Notice Type
- Special Notice
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of the Army, U.S. Army Medical Research Acquisition Activity, U.S. Army Medical Research Acquisition Activity, Attn: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014, Maryland, 21702-5014, United States
- ZIP Code
- 21702-5014
- Solicitation Number
- MTEC-17-03
- Archive Date
- 8/29/2017
- Point of Contact
- Lisa A. Fisher, Phone: 843-760-3356
- E-Mail Address
-
lisa.fisher@ati.org
(lisa.fisher@ati.org)
- Small Business Set-Aside
- N/A
- Description
- RPP for Cellular Therapy for the Treatment of Hemorrhagic Shock (CTTHS) The Medical Technology Enterprise Consortium (MTEC) is excited to post this announcement for a Request for Project Proposals (RPP) aimed to support a Phase II clinical study to evaluate the safety and efficacy of a cellular therapy in the treatment of hemorrhagic shock in severely injured patients. The MTEC mission is to assist the U.S. Army Medical Research and Materiel Command (USAMRMC) by providing cutting-edge technologies and effective materiel life cycle management to transition medical solutions to industry that protect, treat, and optimize Warfighters' health and performance across the full spectrum of military operations. MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transaction Agreement (OTA), Agreement No. W81XWH-15-9-0001, with the U.S. Army Medical Research Acquisition Activity (USAMRAA). MTEC is currently recruiting a broad and diverse membership that includes representatives from large businesses, small businesses, "non-traditional" government contractors, academic research institutions and not-for-profit organizations. This RPP seeks proposals from entities developing technologies for cell therapies that can be used to treat the inflammatory complications that arise after traumatic injury. This request is not looking for cell therapies that can be used to achieve hemostasis. The intent of this action is to forward at least one cell therapy prototype into a Phase II clinical trial. Therefore, the products being brought forth must be ready to enter the clinical stage within a short window and have all of the regulatory requirements for an IND application prepared for submission as a minimum. The focus of this effort is on the actual clinical study. See Attachment
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/MTEC-17-03/listing.html)
- Record
- SN04580017-W 20170716/170714234814-6e023f3b3ddeca34020f11a704b1aadd (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |